A new, orally-administered treatment for an aggressive form of advanced breast cancer has been launched in Sri Lanka by GlaxoSmithKline Pharmaceuticals (GSK) following regulatory approval, the company announced this week.
Tykerb®, (lapatinib) is the first oral, small molecule dual targeted therapy for the treatment of patients with advanced or metastatic breast cancer whose tumours over-express ErbB2, a protein giving higher aggression in breast cancer. It is already authorised for sale in the United States under the brand name Tykerb and for sale in the European Union and Switzerland as Tyverb®.
Clinical trials have established that Tykerb, in combination with capecitabine has significantly increased time to progression in women with locally advanced or metastatic ErbB2-positive breast cancer whose disease had progressed following prior treatment with anthracyclines, taxanes and trastuzumab, the company said in a statement. |
E-mail